NCT05440136View on ClinicalTrials.gov

A Safety Study of LY3462817 in Healthy Japanese and Non-Japanese Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

June 28, 2022

Primary Completion Date

March 8, 2023

Study Completion Date

March 8, 2023

Conditions
Healthy
Interventions
DRUG

LY3462817 (SC)

Administered SC.

DRUG

Placebo (SC)

Administered SC.

DRUG

LY3462817 (IV)

Administered IV.

DRUG

Placebo (IV)

Administered IV.

Trial Locations (1)

90630

Altasciences Clinical Los Angeles, Inc, Cypress

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY